Skip to main content
. Author manuscript; available in PMC: 2014 Aug 6.
Published in final edited form as: Breast Cancer. 2013 Feb 3;20(2):103–110. doi: 10.1007/s12282-013-0446-6

Fig. 2.

Fig. 2

Design and pCR rate of ongoing neoadjuvant studies in HER2-positive breast cancer. IBC inflammatory breast cancer, LABC locally advanced breast cancer, Doce docetaxel, Tz trastuzumab, Pz pertuzumab, FEC 5-fluorouracil, epirubicin, and cyclophosphamide, Pacli paclitaxel, L lapatinib, AC adriamycin and cyclophosphamide, pCR pathologic complete response